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REIMBURSEMENT RECOMMENDATION PROCESS IN BRAZIL: CITEC 
SUBMISSIONS PROFILE
Araújo GTBD, Fonseca M
AxiaBio, São Paulo, Brazil
OBJECTIVES: To access and understand the main characteristics of the Reimburse-
ment submission process and HTA recommendations in Brazil. METHODS: This is 
a crossed analysis of secondary data displayed by the Brazilian new technology incor-
poration committee (CITEC) regarding the quantity and characteristics (disease, sub-
mitter, type of health technology, and year of submission) of the submitted protocols 
versus quantity and characteristics of the recommended health technologies. RESULTS: 
In 3 years of existence, 216 Health technologies (mean of 48 submissions per year) were 
appraised by the commission resulting in 22 positive recommendations and XX Negative 
recommendations. For the reconvened Health technologies, the median time from sub-
mission and recommendation was 1 year. Oncology and Rheumatology are the main 
submissions groups by disease (12% and 11%, respectively) and Hepatology and 
Rheumatology are the most recommended groups by disease (18% and 14% respec-
tively). Manufacturers are the main submitters (74%), followed by the own federal 
government. 5% of the submissions was made by mixed submitters that can be chac-
terized by research partnerships between manufacturers, academia and government. 
CONCLUSIONS: This ﬁ nds suggests that the conduction of HTA recommendation 
and adoption process is already a reality in Brazil and the decisions are based not 
anymore only in political issues but are strongly based on clinical and economical 
issues too. As a new process in the country, modiﬁ cations as time to response and 
establishment of a Brazilian ICER during the next years can improve the results for 
CITEC and submitters.
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Holtorf AP1, Keskinaslan A2, Biskupiak J3, Brixner D4
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OBJECTIVES: To understand how PEOR data are used in decision making today and 
how this may change in future. The methodology and quantity of Pharmacoeconomics 
and Outcomes Research (PEOR) has advanced considerably over the last decade. With 
increasing utilization of health care, prioritization becomes unavoidable and PEOR 
evidence should be increasingly valuable to supplement efﬁ cacy and safety data for 
reimbursement and access decisions. METHODS: An internet based survey with 30 
items was conducted among decision makers from the USA in April 2010. RESULTS: 
The 76 respondents represented organizations with national (54%), regional (32%) or 
local coverage (14%). Membership varied from 50,000 to 100million with a median of 
500,000. While 70% of the respondents claimed that PEOR data are used regularly, 
only 5% indicated coverage by the bylaws of their organizations, and 66% of the users 
indicated that there is no quality standard for PEOR being used by the organization. 
The majority of the respondents expected increasing use of PEOR in the future (77%). 
Organizational requirements to such adoption included ‘more HEOR expertise’, better 
deﬁ nitions and standards of methods, in-house data analysis expertise, and regular re-
evaluation. Outcomes based evidence is increasingly used in contracting (37%) and 73% 
expected an increased use in future with the perceived value of reduced ﬁ nancial and 
clinical risk. CONCLUSIONS: PEOR is used often in decision making in the USA. 
However, few organizations deﬁ ned quality criteria for PEOR. There is a consistent 
expectation that there will be an increasing use of this data, along with a concern 
regarding a lack of expertise to evaluate this information in their organizations. 
Improved standards for quality control of such evidence are needed. Another survey will 
be targeted to the systems and decision makers in selected European countries to 
compare the utilization of PEOR in the different decision making environments.
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ASSESSING THE ADDED VALUE OF NEW DRUGS: A 
MULTIDIMENSIONAL APPROACH
Paladio N, Sunyer B, Almazan C, Solà-Morales O
Catalan Agency for Health Technology and Research, Barcelona, Spain
OBJECTIVES: In November 2008, the Program for the Assessment, Monitoring and 
Reimbursement of High Complexity Drugs (PASFTAC) took effect in Catalonia and 
the Committee for the Assessment of Hospital Use Drugs (CAMUH) was consequently 
appointed to give recommendations on medicines use. Our aim is to develop a tool 
that embraces the multidimensional aspects of added value in drug assessment. 
METHODS: A qualitative approach (adapted expert panel) has been used. Partici-
pants included decision makers, health economists, experts on bioethics, clinicians and 
pharmacists. A previous detailed review of literature was conducted for the topic under 
discussion. RESULTS: Several dimensions and items were identiﬁ ed and discussed in 
a single meeting. Main identiﬁ ed dimensions included efﬁ cacy, safety and cost-effec-
tiveness as well as clinical relevance of outcomes, unmet therapeutic needs, ethics, and 
cost-oportunity. Individual interviews were further conducted. Discussion and rating 
of dimensions and items within these will be performed in a second meeting. A pilot 
test will be conducted after a minimum of 10 drugs are assessed by the CAMUH 
(expected by September 2010). CONCLUSIONS: In a context of limited evidence 
dimensions other than classical efﬁ cacy, safety and cost-effectiveness need to be con-
sidered at the time of assessing added value. This new tool will contribute to that task 
and standardize the process at a local level. 
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APPLICATION OF PERATO’S PRINCIPLE TO UNDERSTAND COST 
DRIVERS IN HEALTH CARE
Long S1, Misra A2
1Thomson Reuters, Cambridge, MA, USA; 2Thomson Reuters, Washington, DC, USA
OBJECTIVES: To determine if Pareto’s principle (also known as the 80–20 rule) applies 
to health care expenditures in the US, and to describe the patients and treatments 
considered to be “cost drivers.” METHODS: The study population consisted of persons 
<65 years that were continuously enrolled in the Thomson Reuters MarketScan Com-
mercial Database during the years 2004–2008. Individuals were rank ordered highest 
to lowest according to their 2008 health care expenditures and assigned to the Cost 
Driver (CD) Cohort if their costs were within the 80% cumulative sum of the overall 
total expenditures. Clinical and cost characteristics were compared between 2004 and 
2008 using Compound Annual Growth Rates (CAGR). RESULTS: 2008 total expen-
ditures were $27.5M among 4.2M covered lives; the CD cohort represented 27% of the 
overall study population. Mean annual expenditures in the CD Cohort were $15,581 
(16.1% CAGR). Outpatient services, inpatient services, and outpatient pharmaceutical 
prescriptions represented 42%, 29% and 28% of total expenditures in 2008. From 2004 
to 2008, pharmaceutical expenditures grew 23% CAGR, while outpatient and inpatient 
expenditure growth was 15% and 13% respectively. Drivers of medical service expen-
ditures in the CD group were visits related to osteoarthritis, renal failure, vaginal deliver-
ies, bone and joint disorders, and low back pain. Drivers of outpatient pharmaceutical 
expenditures in the CD group were antihyperlipidemics, gastrointestinal drugs, antide-
pressants, antidiabetic agents, and anticonvulsants. CONCLUSIONS: In a large US 
database of commercially insured persons, 27% of individuals were accountable for 
80% of health care costs incurred during the year 2008. Payers should consider targeted 
interventions for their cost driver populations; for example, intense targeted programs 
aimed at reducing obesity could yield large cost offsets since much of the incurred costs 
were for treatment of conditions that are sequelae of obesity.
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COSTS OF CARE UNDER A HEALTH CARE PLAN IN THE LAST 5 YEARS 
OF LIFE OF BENEFICIARIES—DATA FROM THE REAL WORLD
Reis Neto J, Stefani S
CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil
OBJECTIVES: To examine, in the ‘real-world’ scenario of a Brazilian health care plan, 
the effect of proximity to death in beneﬁ ciaries on health expenditure during the last 
5 years of life. METHODS: Retrospective analysis from data stored on the comput-
erised system of the health care plan of 1897 beneﬁ ciaries who died between January 
2007 and June 2009. The outpatient and hospital health services in the year of death 
and in the 4 preceding years were examined. The analysis was restricted to total direct 
costs with medical-hospital care. The variables (demographic, clinical and costs) were 
subjected to statistical treatment considering a conﬁ dence interval of 95%. RESULTS: 
Out of a total of 1897 deaths analyzed, the majority were male (60.4%) and were 
aged 60 or over (77.0%). The overall mean age of the deceased was 70.6 years (CI95% 
69.9–71.4). The cost over the 60 months of the study was US$64,427,852. This total, 
66.8% was reimbursed in the year of death and the clinical admissions corresponded 
to 89.2% of the total. Among the main causes of death, neoplasia and chronic diseases 
had a heavier inﬂ uence on expenditure. CONCLUSIONS: The rise in spending on 
health appears to be directly associated with the effect of increased age together with 
a second factor considered to be important, the proximity to death. It is estimated 
that in 2050 Brazil will have a population of 64 million individuals aged 60 or over, 
representing one of the main challenges to the adequate allocation of resources. This 
study suggests that the costs in the last year of life should be considered in the projec-
tions for spending on health care, in the same way as the ageing factor. One of the 
alternatives that appears to be important at the end of life is palliative care.
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COSTS OF TREATING TERMINAL PATIENTS IN DIFFERENT BELGIAN 
HEALTH CARE SETTINGS
Simoens S1, Kutten B2, Menten J2
1K.U. Leuven, Leuven, Belgium; 2University Hospitals Leuven, Leuven, Belgium
OBJECTIVES: This study aims to measure the costs of treating terminal patients in 
Belgian hospitals and in nursing homes from the health care payer perspective. Also, 
this study compares the costs of palliative care with those of usual care. METHODS: 
A multi-centre, retrospective cohort study enrolled patients in acute wards and in 
palliative care units from a representative sample of hospitals and from a representa-
tive sample of nursing homes. Health care costs included ﬁ xed costs and charges 
relating to medical fees, pharmacy and other charges. Data sources consisted of 
hospital and nursing home accountancy data and patient invoice data. The price year 
was 2007/2008. RESULTS: Six hospitals and nineteen nursing homes participated in 
the study, generating a total of 327 patients. Mean hospital costs per patient per day 
amounted to c391 (± c156). Mean hospital costs of patients receiving usual care in 
an acute ward (c340 ± 143) exceeded costs of palliative care in an acute ward (c283 
